Cell cycle-related biomarker lineage promotes the malignant progression of recurrent IDH wild-type glioma
This study developed a cell cycle-related signature for predicting the prognosis of recurrent IDH wild-type glioma, and identified a novel biomarker SYCE2, which could be used to assess the response of patients to TMZ.
Authors
- Wenhua Fan (ORCID: https://orcid.org/0000-0002-3588-2272)
- Jianbao Xu
- Wenping Ma (ORCID: https://orcid.org/0000-0002-1564-4584)
- Hongjun Wang (ORCID: https://orcid.org/0000-0001-7421-1917)
- Ying Zhang (ORCID: https://orcid.org/0000-0002-5812-372X)
- Zhaoshi Bao (ORCID: https://orcid.org/0000-0003-4951-5040)
Institutions
- Harbin Medical University (CN)
- Capital Medical University (CN)
- Chinese National Human Genome Center (CN)
- Beijing Tian Tan Hospital (CN)
- Beijing Institute of Neurosurgery (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s12672-025-04121-7
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00